Dr. D’Angelo on Future Directions With CAR T-Cell Therapy in Lymphoma

Video

Christopher R. D’Angelo, MD, discusses advances made with CAR T-cell therapy in lymphoma.

Christopher R. D’Angelo, MD, an assistant professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center, discusses advances made with CAR T-cell therapy in lymphoma.

Recently, it has been possible to achieve durable remissions and complete responses with CAR T-cell therapy in this patient population, D’Angelo says. This could indicate that this modality may represent a potential curable approach for a refractory population, according to D’Angelo.

Safer CAR T-cell products with increased efficacy and complete, durable responses, are anticipated, D'Angelo notes.

Additionally, the emergence of novel CAR T-cell therapy combinations with agents such as lenalidomide (Revlimid) and ibrutinib (Imbruvica), possess potential, D’Angelo concludes. 

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.